Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 8:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 4,090 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Obstructive Clear all
Terminated Not applicable Interventional

The Pittsburgh Vitamin D Study: Vitamin D Supplementation in Vitamin D-deficient Subjects at Risk of Lung Cancer

NCT02532062
View directory record Official record
Conditions
Deficiency of Vitamin D3, COPD
Interventions
Cholecalciferol, multivitamin, Placebo
Dietary Supplement
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 17, 2026, 8:18 AM EDT
Completed No phase listed Observational

A Registry of COPD Patients to be Used for Future Studies

NCT00814203
View directory record Official record
Conditions
Chronic Obstructive Lung Disease
Interventions
Not listed
Lead sponsor
Philip Diaz
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 17, 2026, 8:18 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children

NCT02377427
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Years to 11 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
San Diego, California • Oklahoma City, Oklahoma • Medford, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 17, 2026, 8:18 AM EDT
Active, not recruiting Phase 1 Interventional

Study to Assess the Safety of DERMASEAL for Diabetic Foot Ulcers

NCT05586542
View directory record Official record
Conditions
Foot Ulcer, Diabetic
Interventions
DERMASEAL, Plasma Film, Standard of Care
Combination Product · Biological · Other
Lead sponsor
Vitruvian Medical Devices, Inc.
Industry
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Fresno, California • South Miami, Florida • Boardman, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 17, 2026, 8:18 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)

NCT01954979
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Abatacept
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 17, 2026, 8:18 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

NCT05767346
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions
Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Placebo to match aficamten, Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg), Placebo to match metoprolol succinate
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
28
States / cities
Anchorage, Alaska • Phoenix, Arizona • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 17, 2026, 8:18 AM EDT
Completed Phase 4 Interventional Results available

Dose-response of Albuterol in Asthmatics

NCT00940927
View directory record Official record
Conditions
Asthma
Interventions
albuterol
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
8 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 1994
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 17, 2026, 8:18 AM EDT
Not listed Not applicable Interventional

RejuvenAir® System Trial for COPD With Chronic Bronchitis

NCT03893370
View directory record Official record
Conditions
Chronic Bronchitis
Interventions
RejuvenAir System, Sham Control Procedure
Device
Lead sponsor
CSA Medical, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
26
States / cities
Scottsdale, Arizona • Mountain View, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 17, 2026, 8:18 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Direct to Patient Minimal Risk Biospecimen and Data Collection Research

NCT07128966
View directory record Official record
Conditions
Healthy, Lupus, Celiac, Kidney Disease, Chronic, Dermatologic
Interventions
Observation
Other
Lead sponsor
Joined Bio
Industry
Eligibility
18 Years to 90 Years
Enrollment
100,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2036
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 17, 2026, 8:18 AM EDT
Terminated Phase 1 Interventional

Phase I Study of Milatuzumab for Graft Versus Host Disease

NCT01663766
View directory record Official record
Conditions
GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL), Myelodysplastic Syndrome, Chronic Myelogenous Leukemia (CML), Multiple Myeloma (MM), Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell), Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)
Interventions
milatuzumab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 17, 2026, 8:18 AM EDT
Completed Not applicable Interventional

Fish Oil to Prevent Asthma Exacerbations in Patients With ALOX5 Polymorphisms

NCT00621829
View directory record Official record
Conditions
Asthma
Interventions
EPA enriched fish oils
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Mather, California
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 17, 2026, 8:18 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair

NCT00927758
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Gainesville, Florida • Iowa City, Iowa • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 17, 2026, 8:18 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma

NCT03406078
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
21
States / cities
Bakersfield, California • Newark, Delaware • Kissimmee, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 17, 2026, 8:18 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Obstructive Sleep Apnea Syndrome on Insulin Sensitivity and Cardiovascular Risk in PCOS Adolescents

NCT01840618
View directory record Official record
Conditions
Obstructive Sleep Apnea Syndrome, Polycystic Ovary Syndrome, Sleep Apnea
Interventions
Nasal Continuous positive airway pressure (CPAP)
Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
13 Years to 21 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 17, 2026, 8:18 AM EDT
Completed Phase 3 Interventional Results available

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B

NCT01323660
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GSK573719 125, GSK573719 62.5, GW642444 25, placebo
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older · Male only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
Jasper, Alabama • Torrance, California • Fort Collins, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 17, 2026, 8:18 AM EDT
Completed Not applicable Interventional Results available

Effect of Nasal Positive Airway Pressure Versus Standard Care on Oxygenation and Ventilation During Propofol-based Sedation for Colonoscopy in Patients With High Risk of Airway Obstruction

NCT05524220
View directory record Official record
Conditions
Obstructive Sleep Apnea, Obesity
Interventions
Standard care with a facemask., SuperNO2VA™EtCO2 (Nasal Oxygenating Ventilating Apparatus)
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 17, 2026, 8:18 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)

NCT01044459
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium Bromide 200 µg, Aclidinium Bromide 400 µg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
110
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 17, 2026, 8:18 AM EDT
Completed Not applicable Interventional Results available

Belun Ring Platform With an Improved Algorithm for OSA Assessment

NCT04885062
View directory record Official record
Conditions
Sleep-Disordered Breathing, Sleep Architecture
Interventions
Belun Ring, PSG
Device · Diagnostic Test
Lead sponsor
Belun Technology Company Limited
Other
Eligibility
18 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 17, 2026, 8:18 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children

NCT00593918
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Up to 24 Months
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Oct 17, 2026, 8:18 AM EDT
Withdrawn Phase 2 Interventional

Phase Analysis and Obstructive CAD on Rubidium PET

NCT01840696
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Regadenoson
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 17, 2026, 8:18 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

IOA Preventing Occlusal Changes With MAD Use

NCT07103941
View directory record Official record
Conditions
Sleep Related Breathing Disorder, Snoring, Obstructive Sleep Apnea (OSA), Open Bite, Occlusal Changes, Tooth Migration, Posterior Open Bite
Interventions
AM Aligner, Exercise
Device · Behavioral
Lead sponsor
Isabel Moreno Hay
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 17, 2026, 8:18 AM EDT
Not yet recruiting No phase listed Observational

Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study

NCT07676097
View directory record Official record
Conditions
Non-obstructive Coronary Disease, Acute or Chronic Coronary Artery Disease
Interventions
Patients with intermediate coronary artery stenosis with clinically indicated FFR assessment., Microvascular assessment
Procedure
Lead sponsor
AngioInsight
Industry
Eligibility
18 Years and older
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 17, 2026, 8:18 AM EDT
Completed Not applicable Interventional Results available

Study of a Sleep Apnea System for the Treatment of Obstructive Sleep Apnea

NCT01146782
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Attune Sleep Apnea System
Device
Lead sponsor
ApniCure, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
6
States / cities
Phoenix, Arizona • Burlingame, California • Menlo Park, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced Oct 17, 2026, 8:18 AM EDT
Completed Not applicable Interventional Results available

Comparative Effectiveness Research to Enhance Outcomes in African-Americans With Obstructive Sleep Apnea

NCT01997723
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Portable monitoring, Polysomnography, Home portable monitoring, Laboratory portable monitoring
Device · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 17, 2026, 8:18 AM EDT